Humanigen (NASDAQ:HGEN) Stock Price Up 3.7%
Humanigen (NASDAQ:HGEN) Stock Price Up 3.7%
Humanigen, Inc. (NASDAQ:HGEN – Get Rating) shares rose 3.7% during trading on Tuesday . The stock traded as high as $0.17 and last traded at $0.17. Approximately 1,205,421 shares were traded during trading, a decline of 59% from the average daily volume of 2,964,703 shares. The stock had previously closed at $0.16.
Humanigen, Inc.(納斯達克股票代碼:HGEN — 獲取評級)股價在週二的交易中上漲了3.7%。該股交易價格高達0.17美元,最後一次交易價格爲0.17美元。交易期間交易了約1,205,421股,較平均每日交易量2,964,703股下降了59%。該股此前收於0.16美元。
Analyst Upgrades and Downgrades
分析師升級和降級
HGEN has been the subject of several analyst reports. Cantor Fitzgerald initiated coverage on Humanigen in a research note on Wednesday, January 11th. They set a "neutral" rating for the company. Credit Suisse Group reissued an "underperform" rating and set a $0.50 target price on shares of Humanigen in a research note on Monday, April 3rd.
HGEN一直是幾份分析師報告的主題。坎託·菲茨傑拉德在1月11日星期三的一份研究報告中開始了對Humanigen的報道。他們爲公司設定了 “中立” 評級。瑞士信貸集團在4月3日星期一的一份研究報告中重新發布了 “表現不佳” 的評級,並將Humanigen股票的目標價格設定爲0.50美元。
Humanigen Trading Up 3.7 %
Humanigen 交易上漲了 3.7%
The firm has a market capitalization of $19.65 million, a PE ratio of -0.11 and a beta of -0.84. The business has a 50 day moving average price of $0.15 and a 200-day moving average price of $0.15.
該公司的市值爲1,965萬美元,市盈率爲-0.11,beta值爲-0.84。該企業的50天移動平均價格爲0.15美元,200天移動平均價格爲0.15美元。
Institutional Investors Weigh In On Humanigen
機構投資者權衡Humanigen
A number of large investors have recently bought and sold shares of the stock. Virtu Financial LLC boosted its holdings in shares of Humanigen by 225.9% during the fourth quarter. Virtu Financial LLC now owns 301,792 shares of the company's stock worth $36,000 after purchasing an additional 209,195 shares during the last quarter. Renaissance Technologies LLC raised its position in Humanigen by 72.3% in the fourth quarter. Renaissance Technologies LLC now owns 1,491,771 shares of the company's stock valued at $179,000 after purchasing an additional 626,071 shares during the period. UBS Group AG raised its position in Humanigen by 293.0% in the fourth quarter. UBS Group AG now owns 206,151 shares of the company's stock valued at $25,000 after purchasing an additional 153,695 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Humanigen by 2,848.4% in the third quarter. Bank of New York Mellon Corp now owns 620,733 shares of the company's stock worth $112,000 after acquiring an additional 599,680 shares in the last quarter. Finally, Telemetry Investments L.L.C. lifted its stake in shares of Humanigen by 584.9% in the third quarter. Telemetry Investments L.L.C. now owns 500,000 shares of the company's stock worth $90,000 after acquiring an additional 427,000 shares in the last quarter. Institutional investors and hedge funds own 6.93% of the company's stock.
許多大型投資者最近買入和賣出了該股的股票。Virtu Financial LLC在第四季度將其持有的Humanigen股票增加了225.9%。Virtu Financial LLC在上個季度又購買了209,195股股票後,現在擁有該公司價值36,000美元的301,792股股票。文藝復興科技有限責任公司在第四季度將其在Humanigen的頭寸提高了72.3%。Renaissance Technologies LLC在此期間又購買了626,071股股票後,現在擁有該公司價值17.9萬美元的1,491,771股股票。瑞銀集團股份公司在第四季度將其在Humanigen的頭寸提高了293.0%。瑞銀集團股份公司在此期間又購買了153,695股股票後,現在擁有該公司206,151股股票,價值25,000美元。紐約銀行梅隆公司在第三季度將其在Humanigen的股份提高了2,848.4%。紐約銀行梅隆公司在上個季度又收購了599,680股股票後,現在擁有該公司620,733股股票,價值11.2萬美元。最後,Telemetry Investments L.L.C. 在第三季度將其在Humanigen的股份提高了584.9%。Telemetry Investments L.L.C. 在上個季度又收購了42.7萬股股票後,現在擁有該公司50萬股股票,價值9萬美元。機構投資者和對沖基金擁有該公司6.93%的股票。
About Humanigen
關於 Humanigen
(Get Rating)
(獲取評級)
Humanigen, Inc, a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called 'cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH.
Humanigen, Inc是一家臨床階段的生物製藥公司,專注於預防和治療一種叫做 “細胞因子風暴” 的免疫過度反應。Lenzilumab 是一種結合並中和粒細胞-巨噬細胞集落刺激因子 (GM-CSF) 的抗體。該公司正在開發lenzilumab作爲治療與 COVID-19 相關的細胞因子風暴的藥物,該公司已經完成了該研究的三期研究,並且是美國國立衛生研究院贊助的2/3期研究的重點。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Humanigen (HGEN)
- United Parcel Service Delivers A Warning To The Market
- Pulte Homes Is Hosting The Better, More Profitable Open House
- Virios Therapeutics Up 75% on Fibromyalgia Phase 3 Proposal
- A Top Is In For McDonald's Corporation Stock
- Strong Demand Makes Cleveland-Cliffs an Undervalued Mid-Cap
- 免費獲取 StockNews.com 關於 Humanigen (HGEN) 的研究報告
- 聯合包裹服務向市場發出警告
- Pulte Homes正在舉辦更好、更有利可圖的開放日
- Virios Therapeutics 因纖維肌痛第 3 階段提案上漲了 75%
- 麥當勞公司股票將達到頂峯
- 強勁的需求使克利夫蘭-克利夫斯成爲被低估的中型股
Receive News & Ratings for Humanigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humanigen and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Humanigen Daily 的新聞和評級 -在下面輸入您的電子郵件地址,即可通過Marketbeat.com的免費每日電子郵件時事通訊接收Humanigen及相關公司的最新新聞和分析師評級的簡明每日摘要。
譯文內容由第三人軟體翻譯。